BCARTB Stock Overview
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biocartis Group NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.71 |
| 52 Week High | €3.62 |
| 52 Week Low | €1.71 |
| Beta | 1.7 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -73.01% |
| 5 Year Change | -86.40% |
| Change since IPO | -74.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| BCARTB | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.7% |
| 1Y | n/a | -8.5% | -1.8% |
Return vs Industry: Insufficient data to determine how BCARTB performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how BCARTB performed against the UK Market.
Price Volatility
| BCARTB volatility | |
|---|---|
| BCARTB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BCARTB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BCARTB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 619 | Herman Verrelst | www.biocartisgroupnv.be |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
Biocartis Group NV Fundamentals Summary
| BCARTB fundamental statistics | |
|---|---|
| Market cap | €68.35m |
| Earnings (TTM) | -€62.96m |
| Revenue (TTM) | €58.61m |
1.2x
P/S Ratio-1.1x
P/E RatioIs BCARTB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCARTB income statement (TTM) | |
|---|---|
| Revenue | €58.61m |
| Cost of Revenue | €73.13m |
| Gross Profit | -€14.52m |
| Other Expenses | €48.45m |
| Earnings | -€62.96m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -24.77% |
| Net Profit Margin | -107.42% |
| Debt/Equity Ratio | -209.9% |
How did BCARTB perform over the long term?
See historical performance and comparison